MAPT and supranuclear palsy, progressive, 1: While flortaucipir is not intended for diagnostic use in neurodegenerative and neurological conditions other than Alzheimer’s disease dementia, it has been used for research purposes.308 Overall, flortaucipir binding elevation has been described in regions in which tau pathology or neurodegeneration would be expected, e.g. basal ganglia in PSP or anterior temporal lobes in semantic variant primary progressive aphasia (svPPA; see below).